首页> 美国卫生研究院文献>American Journal of Translational Research >The clinical efficacy of compound Danshen injection on acute cerebral infarction and on the changes in the CRP D-dimer and IL-6 levels
【2h】

The clinical efficacy of compound Danshen injection on acute cerebral infarction and on the changes in the CRP D-dimer and IL-6 levels

机译:复合丹参注射对急性脑梗塞及CRPD-二聚体和IL-6水平变化的临床疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective: To study the clinical curative effect of compound Danshen injection on acute cerebral infarction (ACI) patients and its impact on the CRP, D-dimer, and IL-6 levels. Methods: 116 patients with ACI admitted to our hospital were randomly placed in an observation group (n=58) or a control group (n=58). The control group received rosuvastatin tablets (10 mg/time, qd) in addition to the standard treatment. The observation group received compound Danshen injection in addition to the standard treatment. The treatment continued for 21 days. The clinical treatment efficacy, the CRP, D-dimer, and IL-6 levels, the NIHSS scores (to evaluate the degree of neurological impairment), the Fugl-Meyer scores (to access patients’ motor function), the ADL scores, the sleep quality (the PSQI and AIS scores), and the complication incidence rates were compared between the two groups. Results: After the treatment, the effective rate in the observation group (89.66%) was significantly higher than it was in the control group (74.14%) (P<0.05). After the treatment, the serum CRP, D-dimer, and IL-6 levels in the two groups were lower than they were before the treatment, and the levels were lower in the observation group than they were in the control group (all P<0.05). After the treatment, the NIHSS scores in the observation group were lower than they were in the control group, and the Fugl-Meyer and ADL scores were higher than they were in the control group (all P<0.05). Compared with the control group, the PSQI and AIS scores in the observation group were lower than they were in the control group after the treatment (P<0.05). The severe diarrhea, bedsore, urinary tract infection, liver and kidney function injury, skin allergic reactions and other total adverse reaction incidence rates in the observation group were lower than they were in the control group. Conclusion: Rosuvastatin combined with compound Danshen injection is effective in ACI treatment. It is able to effectively improve the clinical symptoms, reduce the incidence of complications, improve the recovery of the IL-6, CRP, and D-dimer levels and enhance patients’ sleep quality.
机译:目的:研究复合丹参注射对急性脑梗死(ACI)患者的临床疗效及其对CRP,D-二聚体和IL-6水平的影响。方法:116例ACI患者被院入院,随机置于观察组(n = 58)或对照组(n = 58)中。除标准治疗外,对照组还接受了罗苏伐他汀片剂(10mg / time,QD)。除标准治疗外,观察组还接受了复合丹参注射。治疗持续21天。临床治疗疗效,CRP,D-二聚体和IL-6水平,NIHSS分数(评估神经损伤程度),Fugl-Meyer分数(访问患者的运动功能),ADL分数,睡眠质量(PSQI和AIS分数),两组之间比较了并发症发病率。结果:治疗后,观察组的有效率(89.66%)明显高于对照组(74.14%)(P <0.05)。在治疗后,两组中的血清CRP,D-二聚体和IL-6水平低于治疗前的血清CR-6水平,观察组的水平低于对照组(所有P <) 0.05)。治疗后,观察组的NIHSS分数低于对照组中的分数,并且Fugl-Meyer和ADL分数高于对照组(所有P <0.05)。与对照组相比,观察组中的PSQI和AIS评分低于治疗后对照组中的分数(P <0.05)。严重的腹泻,褥疮,泌尿道感染,肝肾功能损伤,皮肤过敏反应和观察组中的其他总不良反应发生率低于对照组。结论:罗苏伐他汀联合复合丹参注射液在ACI治疗中是有效的。它能够有效改善临床症状,降低并发症的发生率,改善IL-6,CRP和D-二聚体水平的恢复,提高患者的睡眠质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号